Amit G Singal1, Sruthi Patibandla2, Joseph Obi2, Hannah Fullington3, Neehar D Parikh4, Adam C Yopp5, Jorge A Marrero6. 1. Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System, Dallas, Texas; Department of Population Sciences, UT Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas. Electronic address: amit.singal@utsouthwestern.edu. 2. Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System, Dallas, Texas. 3. Department of Population Sciences, UT Southwestern Medical Center, Dallas, Texas. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 5. Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; Department of Surgery, UT Southwestern Medical Center, Dallas, Texas. 6. Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System, Dallas, Texas; Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND & AIMS: The value of a cancer screening programs is defined by its balance of benefits and harms; however, there are few data evaluating both attributes for hepatocellular carcinoma (HCC) surveillance. We aimed to characterize benefits and harms of HCC surveillance in a large prospective cohort of patients with cirrhosis. METHODS: We conducted a secondary analysis of a clinical trial evaluating HCC surveillance among patients with cirrhosis at a safety-net health system enrolled between December 2014 and July 2015. We quantified surveillance-related benefits, defined as early HCC detection and curative treatment receipt, and physical harms, defined as diagnostic procedures for false positive or indeterminate results, over an 18-month period. RESULTS: Of 614 cirrhosis patients with ≥1 surveillance exam, abnormal results were observed in 118 (19.2%) patients. Twenty-six patients developed HCC during follow-up, of whom 16 (61.5%) were detected by surveillance. The proportion of HCC detected at BCLC stage 0/A (62.5% vs 50%, p = .69) and who underwent curative treatment (43.8% vs. 40.0%, p = 1.0) did not significantly differ between surveillance-detected patients and those diagnosed incidentally/symptomatically. Physical harms were observed in 54 (8.8%) patients who underwent surveillance - most of mild severity with only 1 diagnostic CT or MRI and none undergoing invasive testing such as biopsy. Incidental findings on follow-up imaging were found in 40 (6.5%) patients -23 of low clinical importance and 17 medium clinical importance. CONCLUSIONS: In our cohort of patients with cirrhosis, HCC surveillance was associated with high early tumor detection and minimal physical harms.
BACKGROUND & AIMS: The value of a cancer screening programs is defined by its balance of benefits and harms; however, there are few data evaluating both attributes for hepatocellular carcinoma (HCC) surveillance. We aimed to characterize benefits and harms of HCC surveillance in a large prospective cohort of patients with cirrhosis. METHODS: We conducted a secondary analysis of a clinical trial evaluating HCC surveillance among patients with cirrhosis at a safety-net health system enrolled between December 2014 and July 2015. We quantified surveillance-related benefits, defined as early HCC detection and curative treatment receipt, and physical harms, defined as diagnostic procedures for false positive or indeterminate results, over an 18-month period. RESULTS: Of 614 cirrhosis patients with ≥1 surveillance exam, abnormal results were observed in 118 (19.2%) patients. Twenty-six patients developed HCC during follow-up, of whom 16 (61.5%) were detected by surveillance. The proportion of HCC detected at BCLC stage 0/A (62.5% vs 50%, p = .69) and who underwent curative treatment (43.8% vs. 40.0%, p = 1.0) did not significantly differ between surveillance-detected patients and those diagnosed incidentally/symptomatically. Physical harms were observed in 54 (8.8%) patients who underwent surveillance - most of mild severity with only 1 diagnostic CT or MRI and none undergoing invasive testing such as biopsy. Incidental findings on follow-up imaging were found in 40 (6.5%) patients -23 of low clinical importance and 17 medium clinical importance. CONCLUSIONS: In our cohort of patients with cirrhosis, HCC surveillance was associated with high early tumor detection and minimal physical harms.
Authors: Thomas M Gluecker; C Daniel Johnson; Lynn A Wilson; Robert L Maccarty; Timothy J Welch; David J Vanness; David A Ahlquist Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Russell P Harris; Stacey L Sheridan; Carmen L Lewis; Colleen Barclay; Maihan B Vu; Christine E Kistler; Carol E Golin; Jessica T DeFrank; Noel T Brewer Journal: JAMA Intern Med Date: 2014-02-01 Impact factor: 21.873
Authors: Neehar D Parikh; Wesley J Marrero; Jingyuan Wang; Justin Steuer; Elliot B Tapper; Monica Konerman; Amit G Singal; David W Hutton; Eunshin Byon; Mariel S Lavieri Journal: Hepatology Date: 2018-05-14 Impact factor: 17.425
Authors: Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts Journal: Clin Gastroenterol Hepatol Date: 2010-09-08 Impact factor: 11.382
Authors: O Simmons; D T Fetzer; T Yokoo; J A Marrero; A Yopp; Y Kono; N D Parikh; T Browning; A G Singal Journal: Aliment Pharmacol Ther Date: 2016-11-08 Impact factor: 8.171
Authors: Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2013-10-02 Impact factor: 11.382
Authors: Yi-Te Lee; Amit G Singal; Marie Lauzon; Vatche G Agopian; Michael Luu; Mazen Noureddin; Tsuyoshi Todo; Irene K Kim; Marc L Friedman; Kambiz Kosari; Nicholas N Nissen; Lewis R Roberts; Julie K Heimbach; Gregory J Gores; Ju Dong Yang Journal: Cancer Date: 2022-08-23 Impact factor: 6.921
Authors: Colin Dunn; Bo Lin; Nicole E Rich; Madhukar S Patel; Purva Gopal; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2022-03-17 Impact factor: 13.576
Authors: Amit G Singal; Emily Zhang; Manasa Narasimman; Nicole E Rich; Akbar K Waljee; Yujin Hoshida; Ju Dong Yang; Maria Reig; Giuseppe Cabibbo; Pierre Nahon; Neehar D Parikh; Jorge A Marrero Journal: J Hepatol Date: 2022-02-06 Impact factor: 30.083
Authors: Sean A Woolen; Amit G Singal; Matthew S Davenport; Jonathan P Troost; Shokoufeh Khalatbari; Sukul Mittal; Sehar Siddiqui; Austin Fobar; Jason Morris; Mobolaji Odewole; Elliot B Tapper; Anjana Pillai; Neehar D Parikh Journal: Clin Gastroenterol Hepatol Date: 2021-02-19 Impact factor: 13.576